Inventiva S.A.
IVA
Rangering i aksjer
#10677
Inventiva S.A. is a biopharmaceutical firm currently in the clinical... Inventiva S.A. is a biopharmaceutical firm currently in the clinical development phase, specializing in creating orally administered small molecule treatments for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other ailments. Their primary drug candidate, Lanifibranor, has successfully concluded Phase IIb clinical trials for the management of NASH. Furthermore, the company is advancing Odiparcil, a compound that has finished Phase IIa clinical testing specifically for treating the MPS VI subtype. Beyond these, Inventiva maintains a development pipeline featuring several early-stage projects targeting oncology and other medical conditions. Strategic partnerships are in place with AbbVie to address autoimmune diseases, and with Boehringer Ingelheim International GmbH for innovating therapies for idiopathic pulmonary fibrosis. Established in 2011, Inventiva S.A. operates from its headquarters in Daix, France.
Aksjekurs
$3.20
Markedsverdi
$756.52M
Endring (1 dag)
-1.28%
Endring (1 år)
-20.16%
Land
FR
Handel Inventiva S.A. (IVA)
Kategori
Healthcare
Markedsverdi av Inventiva S.A.(IVA)
Markedsverdi: $756.52M
Per October 2026 har Inventiva S.A. en markedsverdi på $756.52M. Dette gjør Inventiva S.A. til det 10677th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Inventiva S.A. fra 2021 til 2026
IVA sammenlignet med topp 5 mest populære stocks
